Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 30, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) investors of a class action representing investors that bought securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"). Agenus investors have until November 5, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=109665&from=3 CLASS PERIOD: January 23, 2023 to July 1 ...

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=109390&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2 ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=109172&from=3 CLASS PERIOD: January 23, 2023 to July 1 ...

Core Viewpoint - Acadia Healthcare is facing legal scrutiny due to allegations of violating federal securities laws, which has led to significant stock price declines and a class action lawsuit against the company [3][4][5]. Group 1: Legal Issues and Allegations - Acadia Healthcare is being investigated for claims that it held patients against their will in its facilities, even when not medically necessary, and subjected many patients to abuse [3]. - The company allegedly deceived insurance providers into covering unnecessary stays, leading to materially false and misleading statements about its business operations [3]. - A New York Times article highlighted that Acadia's practices have raised legal concerns in at least 12 states, with reports of unlawful detentions [4]. Group 2: Stock Performance and Market Reaction - Following the publication of the New York Times article, Acadia Healthcare's stock price fell by 4.5% on September 3, 2024 [4]. - On September 27, 2024, after Acadia disclosed a grand jury subpoena related to its admissions and billing practices, the stock price dropped by 16.36% [5]. Group 3: Class Action and Investor Communication - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $100,000 in Acadia Healthcare to discuss their legal options, with a deadline for lead plaintiff applications set for December 16, 2024 [1]. - The firm is also seeking information from whistleblowers and former employees regarding Acadia's conduct [6].

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., October 19, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=108709&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is November 5, 2024, and participation does not require appointment as a lead plaintiff [2]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEWS ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107867&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...